Limited benefit of antiretroviral resistance testing in treatment-experienced patients
AIDSPublished 19 October 2004
Ermioni T Panidou, Thomas A Trikalinos, John P. A. Ioannidis
Citations46
SJR quartileQ1
SJR score1.21
SNIP0.90
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Evidence for benefit of antiretroviral resistance testing is sparse and limited to small short-term improvements of virologic response, mostly with GART and less with vPART.
Abstract
Evidence for benefit of antiretroviral resistance testing is sparse and limited to small short-term improvements of virologic response, mostly with GART and less with vPART. Current guidelines widely recommending the use of antiretroviral resistance testing in clinical practice are not commensurate with the available evidence.
Keywords
Immunology and MicrobiologyMedicine
BMJBias in meta-analysis detected by a simple, graphical test
56,268 Citations1997Matthias Egger, George Davey Smith +2 more
Funnel plots, plots of the trials' effect estimates against sample size, are skewed and asymmetrical in the presence of publication bias and other biases Funnel plot asymmetry, measured by regression analysis, predicts discordance of results when meta-analyses are compared with single large trials.
Controlled Clinical TrialsMeta-analysis in clinical trials
39,316 Citations1986Rebecca DerSimonian, Nan M. Laird
This paper examines eight published reviews each reporting results from several related trials in order to evaluate the efficacy of a certain treatment for a specified medical condition and suggests a simple noniterative procedure for characterizing the distribution of treatment effects in a series of studies.
Statistics in MedicineQuantifying heterogeneity in a meta‐analysis
36,744 Citations2002Julian P. T. Higgins, Simon G. Thompson
It is concluded that H and I2, which can usually be calculated for published meta-analyses, are particularly useful summaries of the impact of heterogeneity, and one or both should be presented in publishedMeta-an analyses in preference to the test for heterogeneity.
BiometricsOperating Characteristics of a Rank Correlation Test for Publication Bias
17,035 Citations1994Colin B. Begg, Madhuchhanda Mazumdar
An adjusted rank correlation test is proposed as a technique for identifying publication bias in a meta-analysis, and its operating characteristics are evaluated via simulations, and the test statistic is a direct statistical analogue of the popular "funnel-graph".
Annals of Internal MedicineQuantitative Synthesis in Systematic Reviews
2,477 Citations1997Joseph T. F. Lau, John P.A. Ioannidis +1 more
A stepwise description of the tasks that are performed when statistical methods are used to combine data and the question, Are the results of the different studies similar (homogeneous)?
Journal of Clinical EpidemiologyThe results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials
2,002 Citations1997Heiner C. Bucher, Gordon Guyatt +2 more
An alternative model is presented that evaluates the differences between treatment and placebo in two sets of clinical trials, and preserves the randomization of the originally assigned patient groups.
BMJValidity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses
946 Citations2003Fujian Song, Douglas G Altman +2 more
Results of adjusted indirect comparison usually, but not always, agree with those of head to head randomised trials The validity ofadjusted indirect comparisons depends on the internal validity and similarity of the trials involved.
The LancetDrug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial
760 Citations1999J. Durant, Philippe Clevenbergh +8 more
Genotypic-resistance testing is found to have a significant benefit on the virological response when choosing a therapeutic alternative for HIV-1-infected patients in whom combination therapy was not successful.
JAMAAntiretroviral Treatment for Adult HIV Infection in 2002
711 Citations2002Patrick Yéni, Scott M. Hammer +16 more
Because of increased awareness of the activity and toxicity of current drugs, the threshold for initiation of therapy has shifted to a later time in the course of HIV disease, however, the optimal time to initiate therapy remains imprecisely defined.
Clinical Infectious DiseasesAntiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA Panel
516 Citations2003Martin Hirsch, Françoise Brun‐Vézinet +11 more
The International AIDS Society-USA convened a panel of physicians and scientists with expertise in antiretroviral drug management, HIV-1 drug resistance, and patient care to provide updated recommendations for HIV- 1 resistance testing.
AIDSA randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
502 Citations2000John D. Baxter, Douglas L. Mayers +10 more
A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy in patients failing therapy.
AIDSClinical utility of HIV-1 genotyping and expert advice: the Havana trial
312 Citations2002Cristina Tural, Lı́dia Ruiz +8 more
HIV-1 genotyping interpreted by a software package improves the virological outcome when it is added to the clinical information as a basis for decisions on changing antiretroviral therapy.
AIDSPhenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial
244 Citations2002Jean‐Luc Meynard, Muriel Vray +11 more
Overall, resistance assays did not demonstrate benefit over standard of care, but in patients with the most limited protease inhibitor experience, a significant benefit was observed in the genotyping arm.
AIDSImportance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study
223 Citations2000J. Durant, Philippe Clevenbergh +7 more
Multiple parameters determine the response to antiretroviral therapy and causes other than the development of drug resistance should be considered in the setting of therapeutic failure.
AIDSUsefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA)
215 Citations2002Antonella Cingolani, Andrea Antinori +7 more
The virological benefit of genotype-guided treatment decisions in heavily pre-exposed patients was short term, and patients adherence and residual treatment options influenced outcomes.
AIDSA randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy
197 Citations2002Calvin Cohen, Susan C. Hunt +10 more
Antiretroviral treatment guided prospectively by PRT led to the increased use of ‘active’ antireTroviral agents and was associated with a significantly better virological response.
JAIDS Journal of Acquired Immune Deficiency SyndromesReal Versus Virtual Phenotype to Guide Treatment in Heavily Pretreated Patients: 48-Week Follow-Up of the Genotipo-Fenotipo di Resistenza (GenPheRex) Trial
63 Citations2003Francesco Mazzotta, Sergio Lo Caputo +12 more
Clinical Infectious DiseasesLong‐Term Efficacy of Routine Access to Antiretroviral‐Resistance Testing in HIV Type 1–Infected Patients: Results of the Clinical Efficacy of Resistance Testing Trial
61 Citations2004Scott A. Wegner, Mark R. Wallace +19 more
It is suggested that routine access to resistance testing can improve long-term virologic outcomes in HIV-infected patients who are treatment experienced but may not impact outcome in Patients who are naive to or have had limited experience with ART.
Antiviral TherapyPhenotype or Virtual Phenotype for Choosing Antiretroviral Therapy after Failure: A Prospective, Randomized Study
57 Citations2003Marı́a Jesús Pérez-Elı́as, Isabel García-Arata +15 more
Virtual phenotype is at least as effective as phenotype when used to select an optimized treatment for patients who have failed one or more antiretroviral regimens.
HIV Clinical TrialsAntiretroviral drug resistance testing in patients with HIV-1 infection: A meta-analysis study
51 Citations2002Donato Torre, Roberto Tambini
The results support the use of a genotypic test in patients experiencing virological failure during antiretroviral treatment and expert interpretation of the test may increase the probability of virology response.
AIDSBoth baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy
44 Citations2002John D. Baxter, Thomas C. Merigan +7 more
In salvage therapy, both the number of active drugs and the DL for each drug in the new regimen determine the antiviral response.
JAIDS Journal of Acquired Immune Deficiency SyndromesEconomic Evaluation of Drug Resistance Genotyping for the Adaptation of Treatment in HIV-Infected Patients in the VIRADAPT Study
44 Citations2000Carine Chaix, Catherine Grenier‐Sennelier +5 more
The cost of drug resistance testing is offset by a reduced use of protease inhibitors and their attendant costs, and this trend in the reduction of drug costs and drug use presents a great interest for future trials.
AIDSEuropean guidelines for the clinical management and treatment of HIV-infected adults in Europe
44 Citations2003The EACS Euroguidelines Group
Clinical Infectious DiseasesSuitable Monitoring Approaches to Antiretroviral Therapy in Resource‐Poor Settings: Setting the Research Agenda
36 Citations2003David M. Kent, Donnie McGrath +2 more
Research to identify monitoring strategies that provide the greatest benefit to those living with human immunodeficiency virus in resource-limited settings and that use the available technologies and resources needs to be conducted within a conceptual and ethical framework that takes into account differences between rich and poor countries.
JAIDS Journal of Acquired Immune Deficiency SyndromesEconomic Evaluation of Drug Resistance Genotyping for the Adaptation of Treatment in HIV-Infected Patients in the VIRADAPT Study
14 Citations2000Carine Chaix, Catherine Grenier‐Sennelier +5 more
The cost of drug resistance testing is offset by a reduced use of protease inhibitors and their attendant costs, and this trend in the reduction of drug costs and drug use presents a great interest for future trials.
Clinical Infectious DiseasesKnowledge of Genotypic Resistance Mutations Among Providers of Care to Patients with Human Immunodeficiency Virus
12 Citations2003Carlos Salama, Maurice Policar +1 more
Clinician knowledge of genotypic resistance mutations in human immunodeficiency virus was most deficient among providers caring for or =100 patients.